Ayush Ministry has said that scientists have found that AYUSH 64 is useful in the treatment of asymptomatic, mild and moderate COVID-19 infection as an adjunct to standard care. AYUSH 64 is a poly herbal formulation developed by the Central Council for Research in Ayurvedic Sciences. Initially the drug was developed for Malaria in the year 1980 and now is repurposed for COVID-19. Ayush Ministry and Council of Scientific and Industrial Research in collaboration have completed a robust multi-centre clinical trial to evaluate it’s safety and efficacy.
Director, Centre for Rheumatic Diseases, Pune and honorary chief clinical coordinator of the Ministry of Ayush – CSIR collaboration, Dr Arvind Chopra stated that AYUSH 64 as an adjunct to standard of care showed significant improvement and thus lesser period of hospitalization as compared to standard of care alone. He also said that significant beneficial effects on general health, fatigue, anxiety, stress, appetite, general happiness and sleep were also observed. He also added that patients on AYUSH 64 will still require monitoring so as to identify any worsening of disease.
National Research Professor, Ayush and Chairman of the Inter-disciplinary Ayush Research and Development Task Force on COVID-19, Dr. Bhushan Patwardhan said that the results of AYUSH 64 study are highly encouraging where a reasonably good scientific evidence has emerged. He said that this is a time tested, safe and effective ayurvedic medicine. He informed that the results of the clinical trials would soon be published in reputed scientific journals. The Ayush Ministry has said that in the current situation, this positive finding by scientists of reputed research institutions brings a ray of hope.